SCHEMBL25816517

SCHEMBL25816517

CC(C)(C)OC(=O)N1OCC[C@H]1c1ccc(Cl)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
NPSR1 Q6W5P4 3/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
FAAH O00519 2/20 0.37
LMNA P02545 4/20 0.37
TSHR P16473 3/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
ALDH1A1 P00352 3/20 0.37
STS P08842 1/20 0.36
TRPA1 O75762 1/20 0.36
NR3C1 P04150 1/20 0.36
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLB P06746 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338607 1.00 MEN1 (0.37) MEN1KMT2ANPSR1USP2HPGD
Trifluoroacetic Acid SCHEMBL30339088 0.85 MEN1 (0.32) MEN1KMT2ANPSR1USP2HPGD
SCHEMBL18921353 0.84 RIPK1 (0.39) MEN1KMT2ALMNATSHRGAA
SCHEMBL30547518 0.83 GPR119 (0.41)
SCHEMBL25816599 0.83 GPR119 (0.41)
SCHEMBL30339030 0.83 GPR119 (0.41)
SCHEMBL29048236 0.83 GPR119 (0.41)
SCHEMBL30339230 0.82 KMT2A (0.36) MEN1KMT2ANPSR1LMNATSHR
SCHEMBL22210924 0.82 KMT2A (0.36) MEN1KMT2ANPSR1LMNATSHR
SCHEMBL30339025 0.82 KMT2A (0.36) MEN1KMT2ANPSR1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
CN-108602809-B Isoxazolidine derived inhibitors of receptor interacting protein kinase 1(RIPK 1) 戴纳立制药公司 2022-09-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 MEN1 4787/4885KMT2A 3609/4885NPSR1 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.